StocksMedium•5 November 2026•
1 min read
Keros Therapeutics Reports Surprise Q3 Profit Beating Analyst Estimates
Key Facts
1Keros Therapeutics reported quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a $0.96 loss per share.
2The current quarter's earnings of $0.7 per share compare to a loss of $0.18 per share reported a year ago.
Keros Therapeutics reported quarterly earnings of $0.7 per share for the third quarter of 2026. Zacks reported that these results beat the consensus estimate which had projected a loss of $0.96 per share. The current profit compares to a loss of $0.18 per share recorded during the same period last year.
KROS closed at $10.83 on November 4, 2026, ahead of the financial disclosure. The stock experienced a trading range between a low of $10.8 and a high of $11.22 during that session.